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Acute Myocardial Infarction
877-STEMI-SC or 877-783-6472
Adult Critical Care Intensivists
320-309-8132
Behavioral Health Access Nurse
320-255-5774
Hospitalist Program 320-290-8933

CentraCare Clinic Specialties
Allergy 320-654-3650
Bariatric Medicine 320-240-2828
Cardiology & Cardiac Surgery
320-656-7020
Dermatology 320-229-4924
Endocrinology 320-229-5000
Gastroenterology 320-229-4916
Genetic Services 320-654-3654
Infectious Disease 320-240-2204
Internal Medicine 320-240-2203
or 320-229-4928
Maternal & Fetal Medicine
320-656-7024
Neonatology 320-255-5781
Nephrology 320-240-2206
Neurology 320-240-2829
Neurosurgery 320-240-2836
Obstetrics & Gynecology
320-654-3630
Oncology/Hematology
320-229-4907
Pediatric Critical Care 320-255-5781
Pediatrics 320-654-3610
Pulmonology 320-240-2207
Radiation Oncology 320-229-4901
Rheumatology 320-240-2208
Sleep Medicine 320-251-0726
Sports Medicine 320-229-4917
Surgery 320-252-3342
Wound Care 320-656-7100

Physician Referral Line
320-240-2201
800-458-7272

President’s Message

Population health is a way
of delivering care
By David Tilstra, MD
President, CentraCare Clinic
Population health is the new trend in health care these days.
Unfortunately, there is a lot of confusion about what it means
and how it will influence health care.
‘Population health’ is using data to focus on the delivery of necessary
care to a specific patient population. For example, payers are interested
in the insured population. A provider may be interested in his or her
patients with a particular disease like diabetics or CHF. Employers
might be interested in their employed population. Public health might
be interested in a particular geographic area. By analyzing and using
available population data, we can target resources for areas that need
it rather than using a best-guess approach.
For example, instead of targeting all of our diabetic patients to improve
care, data analysis reveals that most of our patients are receiving great
care, but diabetics who speak Spanish in a particular community have
persistently elevated LDL values. A Spanish-speaking diabetic educator
could be put into that clinic/community to educate the population and
determine if there are other needs. In this example, a targeted approach
was used that solves problems without excessive use of scarce resources.
Population health does require that all providers are working together
toward common goals that are well defined and thought out. Ideally,
community resources are identified and used as much as possible and
care is coordinated to the maximum extent possible. Patients could be
engaged to encourage responsibility for their own health. The goal of
population health is to deliver the best care possible and keep people
continued on page 2

BRCA1, BRCA2 and Beyond
By Joy Gustin, MS, Certified Genetic Counselor, CentraCare Clinic
BRCA1 and BRCA2, the first and second hereditary breast
cancer genes, were discovered in 1990 and 1994, respectively.
Since their discovery, more than one million patients have had
BRCA analysis through Myriad Laboratories. Many more have
been tested through other commercial laboratories and through
research. Recognizing individuals with BRCA alterations
and hereditary cancers is critical to ensure appropriate
medical management for these individuals and their families.

risk gene(s). Several moderate risk breast
cancer genes have been identified including
PALB2, ATM, NBN, RAD51C, CHEK2,
BARD1 and BRIP1.
For more than 30 years, Sanger sequencing
was practically the only sequencing method used for BRCA
analysis. This labor-intensive process is expensive and has
slow turnaround times. When additional testing is required,
the costs and time of results rise dramatically.

The National Comprehensive Cancer Network recommends
BRCA analysis for women diagnosed with breast cancer
The demand for cheaper and faster sequencing methods
before age 45 and women with epithelial ovarian cancer at
began in 2005, but only recently has become available
any age (regardless of family history), women with triple
clinically on a widespread basis. Known as Next Generation
negative breast cancers (ER/PR/her2neu negative) before
Sequencing (NGS), this new method can sequence an entire
age 60, women with breast cancer and significant family
genome in less than a day.
histories, men with breast cancer,
and for unaffected individuals who
Approximately 5 to 10 percent of breast
This has led to the development
have significant family histories.
cancer cases are inherited in families.
of
NGS Cancer Panels. Some
(See NCCN Guidelines Genetic/
Hallmarks of hereditary cancers include:
examples include BRCAplus
Familial High Risk Assessment:
which analyzes the six most
Breast and Ovarian Version
• Cancer in two or more close relatives
common hereditary breast cancer
4.2013) When BRCA testing is
on the same side of the family
genes and MyRisk 25 which
negative (meaning no alteration
• Early age at cancer diagnosis (<50)
analyzes
17 genes associated with
is found) additional genetic testing
• Triple negative (ER/PR/her2neu -)
known
hereditary
cancer
is recommended, especially if there
breast cancer
syndromes
and
eight
modifiers
is early onset breast cancer or a
• Ovarian cancer at any age
genes
that
are
associated
with
striking family history.
• Multiple primary cancers in one
familial clustering of breast and/or
individual
ovarian cancer. These tests can be
Not all breast cancer families are
• Bilateral cancers
offered at pricing comparable to
linked to BRCA1 and BRCA2.
• Rare cancers like male breast cancer
or less than BRCA analysis using
Other inherited forms of breast
• Ashkenazi Jewish descent
Sanger
sequencing.
cancer include Cowden syndrome,
Li-Fraumeni syndrome, Peutz-Jeghers
A variety of NGS Cancer Panels are available commercially
syndrome and Hereditary Diffuse Gastric Cancer (which
at this time and this field is evolving rapidly. There are site
often is associated with lobular breast cancer) and result
specific panels for breast, ovarian, colon, pancreatic, and
from alterations in the PTEN, p53, STK11 and CDH1
renal cancers. There are general panels that test for 25 to 250
genes, respectively.
genes known to be associated with cancer.
Another 15 to 20 percent of breast cancer cases are believed
to be familial (or a result of a family clustering). Females in The interpretation of genetic testing for cancer susceptibility
always has been complex. With the inclusion of additional
these families are at moderate risk for breast cancer. These
genes in the analysis, the interpretation can be especially
family clusters likely result from alterations in moderate
challenging, particularly when variants of uncertain
significance are found. The results must be interpreted
in context of the personal and family history.
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healthy. It’s a great goal that really wasn’t possible
before data was readily available. It’s also a new way of
delivering care that requires us to rethink how we interact
with patients. Traditional patient care isn’t going away,
but by using population health methods, more effective
care will allow us to thoughtfully deliver the right care
to the right patient at the right time.

Genetic testing (by specific gene(s) and cancer panels)
for cancer susceptibility is offered through CentraCare’s
Familial Cancer Clinic to appropriate individuals with
personal and/or significant family history of cancer.
If you are interested in learning more about this testing
or have patients who are interested in testing, please
contact our Genetics Clinic at 320-654-3654.

Hyperbaric Oxygen Therapy can help heal wounds
By Denise Larson, DO, Medical Director, and Mike Fuecker, Director,
CentraCare Wound Center
Hyperbaric Oxygen Therapy (HBOT) helps the body’s
oxygen-dependent, wound-healing mechanisms function
more efficiently. While enclosed in a chamber at greaterthan-normal atmospheric pressure, patients breathe pure
oxygen, saturating their blood plasma and allowing it to
carry 15 to 20 times the normal amount of healing oxygen
to the body’s tissues.
HBOT also maintains oxygen delivery while blood flow
is improved in the microcirculation by the edema-reducing
effect of vasoconstriction.
Approved indications for HBOT provided by the
CentraCare Wound Center and reimbursed by Medicare,
HMOS and other insurance providers include:
• Diabetic wounds of the lower extremities that meet
the following three criteria:
- Patient has type I or type II diabetes and has
a lower extremity wound due to diabetes

•
•
•
•
•

- Patient has a wound classified as
a Wagner III or higher
- Patient has failed an adequate course
of standard wound therapy
Arterial insufficiency as an adjunct to
revascularization
Chronic refractory osteomyelitis unresponsive
to conventional medical and surgical management
Radiation injury (soft tissue, cystitis, proctitis, enteritis
and osteonecrosis), both treatment of established
disease and prevention and surgical support
Skin graphs and flaps, post-operative support
(limited to outpatient)
Preparation of compromised or failed recipient site
for new graft or flap

To learn more about HBOT services or for a patient
referral, call 320-656-7100 (St. Cloud) or 763-271-2846
(Monticello).

Dual Laser remodels collagen, reduces healing time
By Christina Anderson, MD, FAAD, Dermatologist, CentraCare Clinic
CentraCare Clinic’s Dermatology department recently added
the Fraxel Dual 1550/1927 nm laser. This state-of-the-art
laser refreshes the skin, improves skin tone and texture,
wrinkles, pore size, brown spots, age spots, acne scars and
surgical scars, actinic keratoses (pre-cancers) and melasma.
Fractionation of the laser light results in a non-ablative
treatment that decreases healing time with minimal
downtime. Microscopic laser light columns penetrate the
skin to help remodel collagen, tightening the areas treated.
Patients are pre-treated with a topical anesthetic for minimal
pain. After the laser treatment, patients experience a mild
sunburn-like reaction with redness and slight swelling

lasting a day or two followed by peeling
of the treated areas. Most patients are
completely healed in a few days.
The addition of this laser complements other
treatments we offer, such as pulsed dye laser
(for redness, rosacea, hemangiomas, birthmarks);
Gentlelase laser (for brown spots and hair removal); fillers
(Restylane, Perlane, Juvederm, Belotero, Radiesse, and
Voluma) and Botox.
If you have a patient who may be appropriate for any
of our laser or skin-enhancing procedures, please call
CentraCare Clinic Dermatology at 320-229-4924.

Introducing our new CentraCare Clinic Specialist
Radiation Oncology

Coborn Cancer Center, 320-229-4901

Daniel J. Ferraro, MD, PhD
Medical School: University of Iowa Carver College of Medicine, Iowa City
Residency: Washington University, St. Louis, Mo.
Board Eligible: Radiation Oncology
Clinical Interests: Head and Neck Cancers, Lung Cancers, CNS tumors, Stereotactic
Body Radiotherapy, Image Guided Radiotherapy, Intensity Modulated Radiotherapy,
Stereotactic Radio Surgery
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Medicare changes coverage for routine pre-operative
screening services
By Connie Goulet, CPC; Lindsey Theisen, RHIT; Sue Stein, CPC; and Jessica Timmer, CPC,
Compliance Specialists, CentraCare Clinic
Effective Sept. 7, 2013, National Government Services
(the Medicare contractor for Minnesota) no longer reimburses
pre-operative screening services in which the indication is
not clearly documented.

If the indication is clearly for screening purposes only,
an ABN must be obtained from the patient.
In addition, National Government Services has updated
the Removal of Benign Skin Lesions and Trigger Point
Injections policies, please review the links below:

The new policy states:
• The use of diagnostic testing as part of a pre-operative
examination, where there is an absence of signs or
symptoms indicating a need for the test, is not covered
under the Medicare benefit. Such studies will be
considered not reasonable and medically necessary.

Removal of Benign Skin Lesions:
Go to ngsmedicare.com, select Medical Policy Center link,
in the Search Box type - LCD for Removal of Benign Skin
Lesions (L27362).

• Routine Pre-operative Screening Codes will no longer
be covered for the following services: Chest X-ray, EKG,
Partial Thromboplastin, Prothrombin Time, Serum Iron.

Trigger Point Injections:
Go to ngsmedicare.com, select Medical Policy Center link, in
the Search Box type - LCD for Pain Management (L28529).

When ordering any of these services, the indication should
be any sign or symptom, chronic disease or if the reason is
clearly a screening, please document this to support the order.

Within this same search, you also will see a link for additional
instructions to Trigger Point Injections - Article for Pain
Management - Supplemental Instructions Article (A48042).

